Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors
Phase of Trial: Phase I/II
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Pexidartinib (Primary) ; Sirolimus
- Indications Nerve sheath neoplasms; Sarcoma
- Focus Adverse reactions; First in man; Therapeutic Use
- 30 Jan 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2021.
- 19 Sep 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
- 19 Sep 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.